Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer

Annals of Oncology

Volumn 15, Issue 2, 2004, Pages 247-251

  Ramalingam, S ^a   Belani, C P ^a   Day, R ^a   Zamboni, B A ^a   Jacobs, S A ^a   Jett, J R ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Paclitaxel; Small cell lung cancer; Topotecan

Indexed keywords

CISPLATIN; CREATININE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; ILEUS; LEUKOPENIA; LUNG SMALL CELL CANCER; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 1342267618     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh061     Document Type: Article

References (19)

1. Murren J, Glatstein E, Pass HI. Small cell lung cancer. In DeVita Jr VT, Heilman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, Vol. 1. Philadelphia, PA: Lippincott 2001; 983-1018.
2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. J Clin Oncol 1990; 8: 1563-1574.
3. Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Expert Opin Pharmacother 2001; 2: 491-505.
4. Ulukan H, Swaan PW. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002; 62: 2039-2057.
5. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1430-1435.
6. Kirschling RJ, Grill JP, Marks RS et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 1999; 22:517-522.
7. Kaufmann SH, Peereboom D, Buckwalter CA et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734-741.
8. Schutte W, Bork I, Ohlmann K et al. Phase II study: first line treatment of stage IV small cell lung cancer with topotecan and paclitaxel. Proc Am Soc Clin Oncol 2001; 20: 283b.
9. Lynch TJ, Herndon JE, Lyss AP et al. Paclitaxel + topotecan + GCSF for previously untreated extensive small cell lung cancer: preliminary analysis of cancer and leukemia Group B (CALCG) 9430. Proc Am Soc Clin Oncol 2000; 19: 491a.
10. Tweedy CR, Andrews DF, Ball T. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy. Proc Am Soc Clin Oncol 1999; 18: 525a.
11. Jett JR, Bernath AM, Hillman SL et al. Oral topotecan and paclitaxel with G-CSF support in patients with untreated extensive stage small cell (ED-SCLC): a phase II trial of the NCCTG. Proc Am Soc Clin Oncol 2002; 21: 326a.
12. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
13. Sundstrom S, Bremnes RM, Kaasa S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20: 4665-4672.
14. Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-861.
15. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
16. Niell HB, Herndon JE, Miller AA et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 2002; 21: 293a.
17. Schiller JH, Adak S, Cella D et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 2114-2122.
18. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9: 499-508.
19. Jett JR, Hatfield AK, Hillman S et al. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Cancer 2003; 97: 2498-2503.